CIK 0002010788 · <br>Emerging growth company
EXOZYMES INC.
Sign in to watch- Ticker
- EXOZ
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 834550057
- Phone
- (626) - 415 - 1488
- Business address
- 750 ROYAL OAKS DR, MONROVIA, CA, 91016
- Former names
- Invizyne Technologies Inc
- Open-market buys, last 90 days
- $6,405
- in 1 filing
- Open-market sales, last 90 days
- $19,427
- in 1 filing
Net −$13,021. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-12 | Perriman Damien Alan Chief Commercial Officer | Sale | −3,729 | $5.21 | $19K | 28,692 |
| 2026-10-09 | Perriman Damien Alan Chief Commercial Officer | Option exercise | +3,922 | 32,421 | ||
| 2026-10-09 | Perriman Damien Alan Chief Commercial Officer | Option exercise · Restricted Stock Unit | −3,922 | 39,225 | ||
| 2026-10-01 | Rayo Edgardo Javier Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2026-10-01 | MARLETT CHRISTOPHER A Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2026-10-01 | Lalonde James Joseph Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2026-10-01 | DIGIANDOMENICO ANTHONY Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2026-10-01 | Bowie James Ulrich Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2026-10-01 | BELL LON E Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2026-09-14 | Nawaz Fouad Vice President- Finance | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2026-08-26 | Heltzen Michael Chief Executive Officer | Purchase | +4 | $7.58 | $30 | 14,708 |
| 2026-08-26 | Heltzen Michael Chief Executive Officer | Purchase | +251 | $7.35 | $2K | 14,704 |
| 2026-08-26 | Heltzen Michael Chief Executive Officer | Purchase | +250 | $7.60 | $2K | 14,453 |
| 2026-08-25 | Heltzen Michael Chief Executive Officer | Purchase | +250 | $7.52 | $2K | 14,203 |
| 2026-08-25 | Heltzen Michael Chief Executive Officer | Purchase | +100 | $7.50 | $750 | 13,953 |
| 2026-08-19 | Heltzen Michael Chief Executive Officer | Grant or award | +8,841 | $6.40 | $57K | 13,853 |
| 2026-08-19 | Perriman Damien Alan Chief Commercial Officer | Option exercise | +19,612 | 28,499 | ||
| 2026-08-19 | Perriman Damien Alan Chief Commercial Officer | Option exercise · Restricted Stock Unit | −19,612 | 43,147 | ||
| 2026-08-19 | Korman Tyler Paz Chief Scientific Officer | Option exercise | +32,964 | 762,837 | ||
| 2026-08-19 | Korman Tyler Paz Chief Scientific Officer | Option exercise · Restricted Stock Unit | −32,964 | 46,140 |
Page 1 of 2 · 38 trades